» Articles » PMID: 17547682

The Leu544Ile Polymorphism of the Growth Hormone Receptor Gene Affects the Serum Cholesterol Levels During GH Treatment in Children with GH Deficiency

Overview
Specialty Endocrinology
Date 2007 Jun 6
PMID 17547682
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The cellular effects of growth hormone (GH) are mediated by the interaction between GH and the GH receptor (GHR). We investigated the association between polymorphisms in GHR and changes in height standard deviation scores (SDS), and lipid metabolism during GH treatment for GH-deficient children.

Design: A 1-year study on growth rate and lipid metabolism under GH treatment.

Patients: Eighty-three children (61 boys and 22 girls) with GH deficiency were treated with GH for 1 year after diagnosis.

Intervention: The patients were treated with recombinant human GH (0.19 mg/kg/week) for at least 1 year after diagnosis. The growth rates and biochemical parameters for lipid metabolism were measured both before and during treatment. Four single nucleotide polymorphisms (SNPs) in the GHR gene, Cys440Phe, Pro495Thr, Leu544Ile and Pro579Thr, and exon 3 deletion polymorphisms were genotyped by direct sequencing and multiplex PCR.

Results: We found no significant association between GHR polymorphisms and changes in height SDS during GH treatment. The total cholesterol levels of the GH-deficient boys with Ile/Ile at codon 544 showed significantly higher cholesterol levels before GH treatment and then maintained high levels during the GH treatment, compared to those with other genotypes. No other polymorphisms seemed to have any apparent effects on lipid metabolism.

Conclusion: The Leu544Ile polymorphism of the GHR gene is associated with cholesterol levels in boys with GH deficiency.

Citing Articles

Case Report: A Clinical and Genetic Analysis of Childhood Growth Hormone Deficiency With Familial Hypercholesterolemia.

Yang S, Ke X, Liang H, Li R, Zhu H Front Endocrinol (Lausanne). 2021; 12:691490.

PMID: 34220717 PMC: 8249922. DOI: 10.3389/fendo.2021.691490.


Relationship between initial treatment effect of recombinant human growth hormone and exon 3 polymorphism of growth hormone receptor in Chinese children with growth hormone deficiency.

Zheng Z, Cao L, Pei Z, Zhi D, Zhao Z, Xi L Int J Clin Exp Med. 2015; 8(5):7965-70.

PMID: 26221355 PMC: 4509300.


The exon 3-deleted growth hormone receptor: molecular and functional characterization and impact on GH/IGF-I axis in physiological and pathological conditions.

Filopanti M, Giavoli C, Grottoli S, Bianchi A, De Marinis L, Ghigo E J Endocrinol Invest. 2012; 34(11):861-8.

PMID: 22322534 DOI: 10.1007/BF03346731.


Isolated GHD: investigation and implication of JAK/STAT related genes before and after rhGH treatment.

Trovato L, Riccomagno S, Prodam F, Genoni G, Walker G, Moia S Pituitary. 2011; 15(4):482-9.

PMID: 22038029 DOI: 10.1007/s11102-011-0354-8.


The distribution of exon 3-deleted/full-length growth hormone receptor polymorphism in the Turkish population.

Bas F, Kelesoglu F, Timirci O, Kabatas Eryilmaz S, Bozkurt N, Aydin B J Clin Res Pediatr Endocrinol. 2011; 3(3):126-31.

PMID: 21911325 PMC: 3184513. DOI: 10.4274/jcrpe.v3i3.25.